IP Library Granted Patent US 8,318,703
Granted Patent B2
US 8,318,703 · App. 11/446,417 · Granted Nov 27, 2012

Methods for improving kidney function

Assignee: FibroGen, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,318,703
App. No.
11/446,417
Granted
Nov 27, 2012
Kind
B2
Abstract

The invention relates to methods for improving renal (kidney) function. Methods for decreasing blood urea nitrogen (BUN), for increasing glomerular filtration rate (GFR), and for decreasing serum creatinine are also provided.

Claims (10)

1. A method for improving kidney function in a subject having impaired kidney function, the method comprising administering to the subject an effective amount of an agent that inhibits hypoxia inducible factor (HIP) hydroxylase activity.

2. The method of claim 1 , wherein the subject is a mammalian subject.

3. The method of claim 1 , wherein the subject is a human subject.

4. The method of claim 1 , wherein the subject has or is at risk for having an acute or chronic kidney disease.

5. The method of claim 1 , wherein the acute or chronic kidney disease is acute kidney failure or chronic kidney failure.

6. The method of claim 1 , wherein the subject has diabetes.

7. The method of claim 1 , wherein the subject has hypertension.

8. A method for increasing glomerular filtration rate (GFR) in a subject having a decreased GFR, the method comprising administering to the subject an effective amount of an agent that inhibits RIF hydroxylase activity.

9. The method of claim 8 , wherein the decreased GFR is selected from the group consisting of: below about 116 ml/min/1.73 m 2 ; below about 107 ml/min/1.73 m 2 ; below about 99 ml/min/1.73 m 2 ; below about 93 ml/min/1.73 m 2 ; below about 85 ml/min/1.73 m 2 ; and below about 75 ml/min/1.73 m 2 .

10. The method of claim 8 , wherein the increasing GFR comprises increasing GFR to a level selected from the group consisting of: above about 15 ml/min/1.73 m 2 ; above about 30 ml/min/1.73 m 2 ; above about 60 ml/min/1.73 m 2 ; and above about 90 ml/min/1.73 m 2 .

Assignments (4)
CHANGE OF NAME Recorded Feb 18, 2026
From: FIBROGEN, INC.
To: KYNTRA BIO, INC.
Reel/Frame 074923/0352 →
RELEASE OF SECURITY INTEREST Recorded Sep 3, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
To: FIBROGEN, INC.
Reel/Frame 072785/0760 →
SECURITY INTEREST Recorded May 1, 2023
From: FIBROGEN, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 063504/0221 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2007
From: KLAUS, STEPHEN J.; WANG, QINGJIAN; NEFF, THOMAS B.
To: FIBROGEN, INC.
Reel/Frame 020292/0049 →
Continuity (6)
Continuation In Part 10313551 · Dec 6, 2002
Provisional Application 60386488 · Jun 5, 2002
Provisional Application 60359683 · Feb 25, 2002
Provisional Application 60349659 · Jan 16, 2002
Provisional Application 60337082 · Dec 6, 2001
Related Publication 20120149712A1 · Jun 14, 2012